Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr 15;14(4):8213-27.
doi: 10.3390/ijms14048213.

The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer

Zachary C Dobbin  1 , Charles N Landen
Affiliations
Review

The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer

Zachary C Dobbin et al. Int J Mol Sci. .

Abstract

Ovarian cancer is the fifth most common cause of death due to cancer in women despite being the tenth in incidence. Unfortunately, the five-year survival rate is only 45%, which has not improved much in the past 30 years. Even though the majority of women have successful initial therapy, the low rate of survival is due to the eventual recurrence and succumbing to their disease. With the recent release of the Cancer Genome Atlas for ovarian cancer, it was shown that the PI3K/AKT/mTOR pathway was one of the most frequently mutated or altered pathways in patients' tumors. Researching how the PI3K/AKT/mTOR pathway affects the progression and tumorigensis of ovarian cancer will hopefully lead to new therapies that will increase survival for women. This review focuses on recent research on the PI3K/AKT/mTOR pathway and its role in the progression and tumorigensis of ovarian cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011. CA A Cancer J. Clin. 2011;61:212–236. - PubMed
    1. Armstrong D.K. Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist. 2002;7:20–28. - PubMed
    1. Badgwell D., Bast R.C., Jr Early detection of ovarian cancer. Dis. Markers. 2007;23:397–410. - PMC - PubMed
    1. Bast R.C., Jr., Brewer M., Zou C., Hernandez M.A., Daley M., Ozols R., Lu K., Lu Z., Badgwell D., Mills G.B., et al. Cancer Prevention, Recent Results in Cancer Research. Vol. 174. Springer; Berlin, Germany: 2007. Prevention and early detection of ovarian cancer: Mission impossible? pp. 91–100. - PubMed
    1. Kobayashi E., Ueda Y., Matsuzaki S., Yokoyama T., Kimura T., Yoshino K., Fujita M., Kimura T., Enomoto T. Biomarkers for Screening, Diagnosis and Monitoring of Ovarian Cancer. Cancer Epidemiol. Biomarkers Prevent. 2012 doi:0.1158/1055-9965.EPI-12-0646. - PubMed

Publication types

MeSH terms

LinkOut - more resources